Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 119823
1. Sridhar AN, Abozaid M, Rajan P, Sooriakumaran P, Shaw G, Nathan S, Kelly JD, Briggs TP: Surgical Techniques to Optimize Early Urinary Continence Recovery Post Robot Assisted Radical Prostatectomy for Prostate Cancer. Curr Urol Rep; 2017 Sep;18(9):71

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical Techniques to Optimize Early Urinary Continence Recovery Post Robot Assisted Radical Prostatectomy for Prostate Cancer.
  • PURPOSE OF REVIEW: A variety of different surgical techniques are thought to impact on urinary continence (UC) recovery in patients undergoing robot assisted radical prostatectomy (RARP) for prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Urol. 2012 Sep;62(3):405-17 [22749852.001]
  • [Cites] Eur Urol. 2011 Jan;59(1):72-80 [20801579.001]
  • [Cites] BJU Int. 2005 Apr;95(6):766-71 [15794779.001]
  • [Cites] Eur Urol. 2012 Nov;62(5):779-90 [22664219.001]
  • [Cites] Neurourol Urodyn. 2010 Apr;29(4):592-5 [19760755.001]
  • [Cites] Eur Urol. 2009 Apr;55(4):892-900 [19171418.001]
  • [Cites] BJU Int. 2012 Sep;110(6):875-83 [22260307.001]
  • [Cites] Int J Urol. 2014 Nov;21(11):1132-7 [24976517.001]
  • [Cites] J Urol. 2003 Jun;169(6):2225-8 [12771755.001]
  • [Cites] Eur Urol. 2011 Feb;59(2):235-43 [20863611.001]
  • [Cites] J Urol. 2013 Mar;189(3):891-8 [23017512.001]
  • [Cites] N Engl J Med. 2016 Oct 13;375(15):1425-1437 [27626365.001]
  • [Cites] Eur Urol. 2016 Mar;69(3):485-95 [26297603.001]
  • [Cites] Urology. 2005 Nov;66(5 Suppl):83-94 [16194712.001]
  • [Cites] Neurourol Urodyn. 2016 Nov;35(8):1034-1039 [26352154.001]
  • [Cites] Eur Urol. 2010 Sep;58(3):407-17 [20825759.001]
  • [Cites] Oncotarget. 2016 Oct 11;7(41):67463-67475 [27634899.001]
  • [Cites] Urology. 2014 Mar;83(3):632-9 [24387929.001]
  • [Cites] N Engl J Med. 2016 Oct 13;375(15):1415-1424 [27626136.001]
  • [Cites] Nat Rev Urol. 2012 Jan 24;9(4):189-95 [22270136.001]
  • [Cites] J Urol. 2017 Feb;197(2):369-375 [27693447.001]
  • [Cites] Eur Urol. 2017 Jun;71(6):936-944 [27720536.001]
  • [Cites] Eur Urol. 2015 Oct;68(4):692-704 [25454614.001]
  • [Cites] Eur Urol. 2016 Aug;70(2):301-11 [26850969.001]
  • [Cites] Arch Ital Urol Androl. 2001 Sep;73(3):127-37 [11822054.001]
  • [Cites] BJU Int. 2016 Jul;118(1):20-34 [26991606.001]
  • [Cites] Urology. 1994 Oct;44(4):530-4 [7941191.001]
  • [Cites] J Endourol. 2012 Apr;26(4):381-6 [22059698.001]
  • [Cites] J Endourol. 2011 Jun;25(6):1025-30 [21568755.001]
  • [Cites] Can Urol Assoc J. 2017 Mar-Apr;11(3-4):E93-E99 [28360954.001]
  • [Cites] JAMA. 2000 Jan 19;283(3):354-60 [10647798.001]
  • [Cites] J Urol. 1998 Dec;160(6 Pt 2):2418-24 [9817395.001]
  • [Cites] Am J Obstet Gynecol. 1994 Jun;170(6):1713-20; discussion 1720-3 [8203431.001]
  • [Cites] Indian J Urol. 2013 Oct;29(4):338-44 [24235797.001]
  • [Cites] Eur Urol. 2011 Aug;60(2):320-9 [21458913.001]
  • [Cites] BJU Int. 2008 Apr;101(7):871-7 [18321319.001]
  • [Cites] Eur Urol. 2006 Jan;49(1):103-11; discussion 111-2 [16314031.001]
  • [Cites] Eur Urol. 2015 Jun;67(6):977-80 [25613153.001]
  • [Cites] Eur Urol. 2013 Dec;64(6):974-80 [23856036.001]
  • [Cites] Int Neurourol J. 2015 Jun;19(2):113-9 [26126441.001]
  • [Cites] World J Urol. 2014 Dec;32(6):1375-83 [24452450.001]
  • [Cites] Urology. 2006 Dec;68(6):1308-12 [17169652.001]
  • [Cites] BJU Int. 2014 Aug;114(2):236-44 [24612011.001]
  • [Cites] Stem Cells Int. 2016;2016:7060975 [26880983.001]
  • [Cites] Eur Urol. 2017 Mar;71(3):368-378 [27394644.001]
  • [Cites] Eur Urol. 2009 Mar;55(3):629-37 [18801612.001]
  • [Cites] Int Neurourol J. 2016 Mar;20(1):69-74 [27032560.001]
  • [Cites] Eur Urol. 2016 Apr;69(4):584-9 [26277303.001]
  • [Cites] Eur Urol. 2017 May;71(5):822-830 [27283216.001]
  • [Cites] J Robot Surg. 2017 Jan 11;:null [28078523.001]
  • [Cites] World J Mens Health. 2013 Aug;31(2):163-9 [24044112.001]
  • [Cites] J Robot Surg. 2009 Oct;3(3):149-53 [20234870.001]
  • (PMID = 28718165.001).
  • [ISSN] 1534-6285
  • [Journal-full-title] Current urology reports
  • [ISO-abbreviation] Curr Urol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Robotic prostatectomy / Surgical techniques / Urinary continence / Urosurgery
  •  go-up   go-down


2. Kim J, Park JS, Ham WS: The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer. Investig Clin Urol; 2017 Sep;58(5):307-316

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer.
  • Oligometastasis has been proposed as an intermediate stage of cancer spread between localized disease and widespread metastasis.
  • The importance of oligometastasis in managing metastatic prostate cancer is that it is possible to treat with a curative aim by metastasis-directed or local therapy in selected patients.
  • However, few studies have shown definitive benefits of metastasis-directed or local therapy in oligometastatic prostate cancer.
  • Review of the available studies suggests that stereotactic radiotherapy (RT) of metastatic lesions in oligorecurrent disease is a feasible and safe modality for managing oligometastatic prostate cancer.
  • Many retrospective studies of metastatic prostate cancer have shown that patients undergoing local therapy seem to have superior overall and cancer-specific survival compared with patients not receiving local therapy.
  • Ongoing prospective randomized trials would be helpful to evaluate the role of local therapy in oligometastatic prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1998 Oct 8;339(15):1036-42 [9761805.001]
  • [Cites] Front Oncol. 2013 Jan 22;2:215 [23346551.001]
  • [Cites] Arch Intern Med. 2006 Feb 27;166(4):465-71 [16505268.001]
  • [Cites] N Engl J Med. 2001 Dec 6;345(23 ):1655-9 [11759643.001]
  • [Cites] J Clin Oncol. 2016 May 10;34(14 ):1652-9 [26951312.001]
  • [Cites] Lancet. 2011 Dec 17;378(9809):2104-11 [22056152.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3475-84 [15337795.001]
  • [Cites] J Urol. 2004 Apr;171(4):1393-401 [15017184.001]
  • [Cites] Rev Urol. 2007;9 Suppl 1:S3-8 [17387371.001]
  • [Cites] Lancet. 2009 Jan 24;373(9660):301-8 [19091394.001]
  • [Cites] Eur Urol. 2015 Jul;68(1):32-9 [25457017.001]
  • [Cites] Asian J Androl. 2012 Mar;14(2):226-31 [22231296.001]
  • [Cites] Eur Urol. 2014 Aug;66(2):243-50 [24680359.001]
  • [Cites] Cell. 2009 Dec 24;139(7):1315-26 [20064377.001]
  • [Cites] Urol Oncol. 2006 Sep-Oct;24(5):396-402 [16962488.001]
  • [Cites] Cancer. 1995 Jun 1;75(11):2727-31 [7743477.001]
  • [Cites] Cancer. 1988 Jan 1;61(1):195-202 [3334948.001]
  • [Cites] J Urol. 2004 Aug;172(2):525-8 [15247720.001]
  • [Cites] Nat Rev Clin Oncol. 2011 Jun;8(6):378-82 [21423255.001]
  • [Cites] J Urol. 2002 Sep;168(3):1008-12 [12187210.001]
  • [Cites] J Natl Cancer Inst. 2015 May 09;107(7):null [25957435.001]
  • [Cites] Clin Genitourin Cancer. 2013 Mar;11(1):27-32 [23010414.001]
  • [Cites] Acta Oncol. 2013 Nov;52(8):1622-8 [23544357.001]
  • [Cites] J Clin Invest. 2013 Nov;123(11):4918-22 [24135135.001]
  • [Cites] J Hematol Oncol. 2012 Jun 28;5:34 [22742411.001]
  • [Cites] Clin Genitourin Cancer. 2013 Dec;11(4):375-84 [23891497.001]
  • [Cites] Eur Urol. 2014 Sep;66(3):602-3 [24821581.001]
  • [Cites] J Urol. 2015 Aug;194(2):378-85 [25711194.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):3-10 [14697414.001]
  • [Cites] Cancer. 2009 Jun 1;115(11):2388-99 [19399748.001]
  • [Cites] J Urol. 2008 Jun;179(6):2212-6; discussion 2216-7 [18423716.001]
  • [Cites] Eur Urol. 2014 Jun;65(6):1058-66 [24290503.001]
  • [Cites] Eur Urol. 2015 May;67(5):819-22 [25246081.001]
  • [Cites] PLoS One. 2016 Jan 25;11(1):e0147191 [26807740.001]
  • [Cites] Eur Urol. 2012 Aug;62(2):213-9 [22502942.001]
  • [Cites] Eur Urol. 2014 Feb;65(2):467-79 [24321502.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1064-73 [24661660.001]
  • [Cites] Eur Urol. 2016 Jan;69(1):9-12 [26189689.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):889-97 [21277113.001]
  • [Cites] Eur Urol. 2011 May;59(5):832-40 [21354694.001]
  • [Cites] JAMA. 2005 Jul 13;294(2):238-44 [16014598.001]
  • [Cites] Eur Urol. 2010 May;57(5):754-61 [20106588.001]
  • [Cites] Prostate. 2017 May;77(6):559-572 [28093791.001]
  • [Cites] Lancet Oncol. 2010 Nov;11(11):1066-73 [20933466.001]
  • [Cites] Lancet. 2012 Dec 8;380(9858):2018-27 [23084481.001]
  • [Cites] J Urol. 2012 Dec;188(6):2219-24 [23083655.001]
  • [Cites] Cancer Epidemiol. 2014 Aug;38(4):435-41 [24802851.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1285-90 [15817329.001]
  • [Cites] Lancet Oncol. 2008 Aug;9(8):808 [18672217.001]
  • [Cites] Eur Urol. 2015 Aug;68(2):325-34 [25108577.001]
  • [Cites] Eur Urol. 2014 Jan;65(1):124-37 [24207135.001]
  • [Cites] JAMA. 1996 Oct 23-30;276(16):1309-15 [8861989.001]
  • [Cites] Radiother Oncol. 2009 Oct;93(1):14-7 [19409636.001]
  • [Cites] Eur Urol. 2017 Aug;72 (2):289-292 [27574820.001]
  • [Cites] Prostate. 2014 Feb;74(3):297-305 [24395565.001]
  • [Cites] Radiat Oncol. 2014 Jun 12;9:135 [24920079.001]
  • [Cites] Urol Oncol. 2013 May;31(4):455-60 [21481619.001]
  • [Cites] J Urol. 2015 Mar;193(3):832-8 [25254935.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):8-10 [7799047.001]
  • (PMID = 28868501.001).
  • [ISSN] 2466-054X
  • [Journal-full-title] Investigative and clinical urology
  • [ISO-abbreviation] Investig Clin Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Korea (South)
  • [Keywords] NOTNLM ; Neoplasm metastasis / Prostatectomy / Prostatic neoplasms / Radiotherapy
  •  go-up   go-down


3. Kuusk T, Pulliainen K, Vaarala MH: External beam radiation for the treatment of castration-resistant prostate cancer following primary hormonal therapy with androgen ablation: Analysis and outcome of 21 patients. Mol Clin Oncol; 2017 Mar;6(3):428-432
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] External beam radiation for the treatment of castration-resistant prostate cancer following primary hormonal therapy with androgen ablation: Analysis and outcome of 21 patients.
  • Patients who undergo early androgen-deprivation therapy for prostate cancer may eventually develop castration-resistant prostate cancer.
  • However, no optimal treatment for non-metastasized castration-resistant prostate cancer has yet been established.
  • In the present retrospective, single-institutional study, the radiotherapy (RT) outcomes were evaluated in patients who underwent androgen-deprivation therapy for non-metastatic prostate cancer and subsequently developed castration-resistant disease.
  • Following a thorough chart review, the data of 21 patients with castration-resistant prostate cancer who were treated between 2000 and 2010 with external beam radiation therapy (EBRT) at a prostate radiation dose of >45 Gy were evaluated.
  • A total of 18 patients succumbed to the disease during follow-up, with a mean survival of 3 years after RT.
  • Prostate-specific survival time was negatively associated with the Gleason score at diagnosis.
  • The prostate-specific antigen (PSA) concentration prior to RT was a prognostic factor for biochemical recurrence of prostate cancer after RT, as well as for prostate cancer-specific survival.
  • Finally, the multivariate analysis revealed that age, PSA concentration prior to RT and a high Gleason score were independent prognostic factors for prostate cancer-specific survival.
  • Overall, our study findings demonstrated that disease progression was common after EBRT for castration-resistant prostate cancer and that survival was limited.
  • However, young patients and those with low-risk disease at the time of diagnosis may benefit from RT.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Urol. 2015 Sep;68(3):386-96 [25484142.001]
  • [Cites] J Cancer Res Clin Oncol. 2013 Nov;139(11):1955-60 [24057645.001]
  • [Cites] Anticancer Res. 2004 Sep-Oct;24(5B):3141-5 [15510602.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):e205-11 [22342096.001]
  • [Cites] J Urol. 2007 Jun;177(6):2106-31 [17509297.001]
  • [Cites] Int J Urol. 1999 Apr;6(4):187-91 [10226836.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23 (9):1962-8 [15774789.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):759-65 [19327908.001]
  • [Cites] BJU Int. 2009 Nov;104(10):1462-6 [19522869.001]
  • [Cites] Ann Intern Med. 2008 Mar 18;148(6):435-48 [18252677.001]
  • [Cites] Am J Clin Oncol. 2004 Jun;27(3):264-8 [15170145.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1708-14 [16544313.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Nov 1;33(4):907-12 [7591901.001]
  • [Cites] Eur Urol. 2014 Feb;65(2):467-79 [24321502.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2015 Jan;27(1):16-21 [25445554.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):372-9 [15145150.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95 [15663992.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):2918-25 [15860850.001]
  • (PMID = 28451427.001).
  • [ISSN] 2049-9450
  • [Journal-full-title] Molecular and clinical oncology
  • [ISO-abbreviation] Mol Clin Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; prostate cancer / radiation / retrospective chart review
  •  go-up   go-down


Advertisement
4. Bell LJ, Eade T, Kneebone A, Hruby G, Alfieri F, Bromley R, Grimberg K, Barnes M, Booth JT: Initial experience with intra-fraction motion monitoring using Calypso guided volumetric modulated arc therapy for definitive prostate cancer treatment. J Med Radiat Sci; 2017 Mar;64(1):25-34
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial experience with intra-fraction motion monitoring using Calypso guided volumetric modulated arc therapy for definitive prostate cancer treatment.
  • INTRODUCTION: Accurate delivery of radiation while reducing dose to organs at risk is essential in prostate treatment.
  • Three patients had Calypso beacons inserted into their prostate.
  • Prostate rotation was largest in the pitch direction and 28 fractions exceeded the 10° tolerance.
  • [MeSH-major] Dose Fractionation. Movement. Prostatic Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / methods

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 The Authors. Journal of Medical Radiation Sciences published by Wiley Publishing Asia Pty Ltd on behalf of Australian Society of Medical Imaging and Radiation Therapy and New Zealand Institute of Medical Radiation Technology.
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1579-85 [20472357.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1099-105 [17336216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1088-98 [17187940.001]
  • [Cites] Med Phys. 2014 Feb;41(2):020702 [24506591.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):1017-25 [25832692.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):477-83 [23523325.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1097-105 [12128107.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):51-63 [12504036.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):528-34 [16690435.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):682-9 [17398026.001]
  • (PMID = 28263041.001).
  • [ISSN] 2051-3909
  • [Journal-full-title] Journal of medical radiation sciences
  • [ISO-abbreviation] J Med Radiat Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; calypso / implementation / intra-fraction motion / prostate / radiation treatment
  •  go-up   go-down


5. Hosni A, Rosewall T, Craig T, Kong V, Bayley A, Berlin A, Bristow R, Catton C, Warde P, Chung P: The effect of bowel preparation regime on interfraction rectal filling variation during image guided radiotherapy for prostate cancer. Radiat Oncol; 2017 Mar 09;12(1):50
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of bowel preparation regime on interfraction rectal filling variation during image guided radiotherapy for prostate cancer.
  • BACKGROUND: This study aimed to investigate the tolerability and impact of milk of magnesia (MoM) on interfraction rectal filling during prostate cancer radiotherapy.
  • METHODS: Two groups were retrospectively identified, each consisting of 40 patients with prostate cancer treated with radiotherapy to prostate+/-seminal vesicles, with daily image-guidance in 78Gy/39fractions/8 weeks.
  • [MeSH-major] Artifacts. Intestine, Small / physiology. Prostatic Neoplasms / radiotherapy. Radiotherapy, Image-Guided / methods

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1611-21 [15590193.001]
  • [Cites] Eur Urol. 2011 Dec;60(6):1133-9 [21889832.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):125-9 [22330997.001]
  • [Cites] Radiother Oncol. 2010 Jun;95(3):277-82 [20451274.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Oct 1;72 (2):456-66 [18374517.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1072-8 [19783378.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):548-53 [16545919.001]
  • [Cites] Strahlenther Onkol. 2014 Aug;190(8):758-61 [24760248.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jun 1;44(3):525-33 [10348281.001]
  • [Cites] Radiother Oncol. 2011 Dec;101(3):471-8 [21903283.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):646-50 [24054874.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1418-24 [17241751.001]
  • [Cites] Radiother Oncol. 1999 Feb;50(2):225-34 [10368047.001]
  • [Cites] Jpn J Radiol. 2009 Jun;27(5):205-12 [19554413.001]
  • [Cites] JAMA. 1997 May 14;277(18):1445-51 [9145716.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):1279-86 [18572088.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):965-73 [15989996.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1405-18 [19616743.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):653-60 [22099039.001]
  • [Cites] Acta Oncol. 2014 Apr;53(4):569-71 [24237391.001]
  • (PMID = 28279179.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Laxatives
  • [Keywords] NOTNLM ; Bowel preparation / Laxative / Prostate cancer / Radiotherapy / Rectum
  •  go-up   go-down


6. Javanmard B, Hassanzadeh Haddad A, Yaghoobi M, Lotfi B: Diode laser ablation of prostate and channel transurethral resection of prostate in patients with prostate cancer and bladder outlet obstruction symptoms. Urol J; 2014 Jul-Aug;11(4):1788-92
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diode laser ablation of prostate and channel transurethral resection of prostate in patients with prostate cancer and bladder outlet obstruction symptoms.
  • PURPOSE: To evaluate the efficacy of diode laser ablation of prostate for treating lower urinary tract symptoms (LUTS) in patients with locally advanced prostate cancer and comparing results with palli­ative transurethral resection of prostate (pTURP).
  • MATERIALS AND METHODS: Thirty-six known cases of locally advanced prostate cancer with a maximum urinary flow rate (Qmax) of 12 mL per second or less and an International Prostate Symptom Score (IPSS) of 20 or more were included in this study.
  • The first group underwent pTURP and for the second group diode laser ablation of prostate was done.
  • CONCLUSION: Diode laser ablation of prostate and pTURP, both improved significantly IPSS, PVR and Qmax.
  • [MeSH-major] Ablation Techniques / instrumentation. Carcinoma / surgery. Lasers, Semiconductor / therapeutic use. Palliative Care. Prostatic Neoplasms / surgery. Prostatism / surgery. Urinary Bladder Neck Obstruction / surgery
  • [MeSH-minor] Aged. Humans. Length of Stay. Male. Middle Aged. Operative Time. Time Factors. Transurethral Resection of Prostate. Urinary Catheterization. Urodynamics

  • Genetic Alliance. consumer health - Bladder cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25194077.001).
  • [ISSN] 1735-546X
  • [Journal-full-title] Urology journal
  • [ISO-abbreviation] Urol J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Iran
  •  go-up   go-down


7. Baten E, van Renterghem K: The Advantages of Transurethral Resection of the Prostate in Patients with an Elevated or Rising Prostate Specific Antigen, Mild or Moderate Lower Urinary Tract Symptoms, Bladder Outlet Obstruction and Negative Prostate Cancer Imaging or Prostate Biopsies: A Prospective Analysis in 105 Consecutive Patients. Curr Urol; 2017 Aug;10(3):140-144
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Advantages of Transurethral Resection of the Prostate in Patients with an Elevated or Rising Prostate Specific Antigen, Mild or Moderate Lower Urinary Tract Symptoms, Bladder Outlet Obstruction and Negative Prostate Cancer Imaging or Prostate Biopsies: A Prospective Analysis in 105 Consecutive Patients.
  • OBJECTIVE: To investigate elevated or rising prostate specific antigen (PSA) as a marker for bladder outlet obstruction (BOO) in patients with minor lower urinary tract symptoms (LUTS) and without prostate cancer.
  • Only patients with minor LUTS [International Prostate Symptom Score (I-PSS) 0-19] and without suspicion for prostate cancer were included.
  • All patients had BOO, shown by full urodynamics, and underwent transurethral resection of the prostate.
  • The mean detrusor pressure at maximum flow was 93.6 cmH<sub>2</sub>O.
  • The mean resected volume was 52 g and the mean prostate biopsy rate was 1.8.
  • Eighty-three of 105 patients (79%) had no malignancy and were diagnosed with BOO due to benign prostate hyperplasia (subgroup 1).
  • Sixteen of 105 patients (15%) were treated for prostate cancer (subgroup 2).
  • CONCLUSION: BOO can cause an elevated or rising PSA in patients with minor LUTS and negative screening for prostate cancer.
  • Transurethral resection of the prostate is an adequate treatment for these patients.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Nov 10;23(32):8152-60 [16278466.001]
  • [Cites] Prostate. 1999 Jun 1;39(4):234-9 [10344212.001]
  • [Cites] Eur Urol. 2008 Dec;54(6):1385-92 [18599187.001]
  • [Cites] Urol Oncol. 2016 Jul;34(7):296-302 [26725249.001]
  • [Cites] Eur Urol. 2011 Jan;59(1):61-71 [21056534.001]
  • [Cites] Urology. 2007 Feb;69(2):215-20 [17320653.001]
  • [Cites] Clin Genitourin Cancer. 2015 Dec;13(6):512-7 [26231912.001]
  • [Cites] J Urol. 2005 Mar;173(3):691-6 [15711245.001]
  • [Cites] Curr Opin Urol. 2016 Jan;26(1):22-7 [26555691.001]
  • [Cites] Prog Urol. 2016 Feb;26(2):129-36 [26643518.001]
  • (PMID = 28878597.001).
  • [ISSN] 1661-7649
  • [Journal-full-title] Current urology
  • [ISO-abbreviation] Curr Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; Bladder outlet obstruction / PdetQmax / Prostate Specific Antigen / Prostate cancer / Transurethral Resection of the Prostate
  •  go-up   go-down


8. Del Monte M, Costantino L, Salvo V, Grompone MD, Pecoraro M, Stanzione A, Campa R, Vullo F, Sciarra A, Catalano C, Panebianco V: MRI/US fusion-guided biopsy: performing exclusively targeted biopsies for the early detection of prostate cancer. Radiol Med; 2017 Oct 26;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI/US fusion-guided biopsy: performing exclusively targeted biopsies for the early detection of prostate cancer.
  • PURPOSE: The aim of this study was to validate the role of MR/Ultrasound Fusion-Guided Targeted Biopsy as a first diagnostic modality in subjects with clinical suspicion of prostate cancer (PCa).
  • MATERIALS AND METHODS: 108 men (age range 46-78 years) with clinical suspicion for PCa (PSA > 4 ng/mL) underwent multiparametric MRI of the prostate (mpMRI) and, when suspicious lesion were found (according to the PIRADSv2 scoring system), targeted biopsy was performed.
  • Overall cancer detection rate (CDR) was 63%.
  • CONCLUSION: Performing exclusively targeted MR/Ultrasound Fusion-Guided biopsies for the diagnosis of PCa in patients with suspicious PSA levels (> 4 ng/mL) increases the detection rate of clinically significant cancer, changing both the therapeutic options and the prognosis.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 29075977.001).
  • [ISSN] 1826-6983
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Keywords] NOTNLM ; Multiparametric magnetic resonance / Prostate cancer / Targeted biopsy
  •  go-up   go-down


9. Nakamura K, Mizowaki T, Inokuchi H, Ikeda I, Inoue T, Kamba T, Ogawa O, Hiraoka M: Decreased acute toxicities of intensity-modulated radiation therapy for localized prostate cancer with prostate-based versus bone-based image guidance. Int J Clin Oncol; 2017 Jul 29;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased acute toxicities of intensity-modulated radiation therapy for localized prostate cancer with prostate-based versus bone-based image guidance.
  • BACKGROUND: Intensity-modulated radiation therapy (IMRT) is a major therapeutic option for localized prostate cancer.
  • Image-guided radiation therapy (IGRT) allows tumor visualization and corrects the errors caused by daily internal movement of the prostate.
  • The current study retrospectively compared the acute toxicities and biochemical tumor control outcomes of prostate IMRT achieved using two IGRT techniques: bony structure-based IGRT (B-IGRT) and prostate-based IGRT (P-IGRT).
  • METHODS: Between February 2011 and July 2014, 96 patients with low- or intermediate-risk prostate cancer were treated using P-IGRT based on cone-beam computed tomography (CBCT; 76 Gy) without fiducial markers.
  • The prostate-specific antigen failure-free survival rates at 3 years were 95.5 and 92.7% for the P-IGRT and B-IGRT groups, respectively (p = 0.534).
  • CONCLUSIONS: IMRT with P-IGRT allows PTV margin reduction without sacrificing tumor control, which successfully reduces acute rectal toxicity compared with IMRT with B-IGRT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28756594.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; Image-guided radiation therapy (IGRT) / Intensity-modulated radiation therapy (IMRT) / Prostate cancer / Rectal toxicity
  •  go-up   go-down


10. Skácelíková E, Feltl D, Cvek J, Jelenová T, Knybel L, Tomášková H: [Stereotactic Body Radiotherapy of Prostate Cancer - Effectiveness and Toxicity]. Klin Onkol; Spring 2017;30(2):121-127
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Stereotactic Body Radiotherapy of Prostate Cancer - Effectiveness and Toxicity].
  • [Transliterated title] Stereotaktická radioterapie karcinomu prostaty - efektivita a toxicita.
  • BACKGROUND: Prostate cancer is the most prevalent cancer in males and its incidence is steadily increasing.
  • Most cases of prostate cancer are diagnosed during the early asymptomatic period, in which case the prognosis is very good.
  • One treatment method for early stage prostate cancer is stereotactic body radiotherapy (SBRT).
  • PATIENTS AND METHODS: A total of 261 patients with low or intermediate risk prostate cancer were treated with SBRT between August 2010 and July 2012.
  • For assessment of quality of life, patients filled out a modified EPIC questionnaire (Expanded Prostate Composite index).
  • CONCLUSION: SBRT is an effective therapeutic modality for early prostate cancer and has acceptable rates of acute and low late toxicity.Key words: prostate cancer - stereotactic body radiotherapy - quality of life The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.
  • [MeSH-major] Prostatic Neoplasms / radiotherapy. Quality of Life. Radiosurgery / methods

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28397507.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] cze
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down






Advertisement